CN119587690A - 用于治疗人癌瘤的单克隆抗体neo-201 - Google Patents

用于治疗人癌瘤的单克隆抗体neo-201 Download PDF

Info

Publication number
CN119587690A
CN119587690A CN202411004231.XA CN202411004231A CN119587690A CN 119587690 A CN119587690 A CN 119587690A CN 202411004231 A CN202411004231 A CN 202411004231A CN 119587690 A CN119587690 A CN 119587690A
Authority
CN
China
Prior art keywords
cells
patient
neo
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411004231.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·M·阿兰
K·Y·曾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biological Products Co ltd
Original Assignee
Precision Biological Products Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biological Products Co ltd filed Critical Precision Biological Products Co ltd
Publication of CN119587690A publication Critical patent/CN119587690A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202411004231.XA 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201 Pending CN119587690A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762581380P 2017-11-03 2017-11-03
US62/581,380 2017-11-03
US201762592778P 2017-11-30 2017-11-30
US62/592,778 2017-11-30
PCT/US2018/059039 WO2019090134A1 (en) 2017-11-03 2018-11-02 Monoclonal antibody neo-201 for the treatment of human carcinomas
CN201880085205.0A CN111670199B (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880085205.0A Division CN111670199B (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Publications (1)

Publication Number Publication Date
CN119587690A true CN119587690A (zh) 2025-03-11

Family

ID=66332711

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411004231.XA Pending CN119587690A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN201880085205.0A Active CN111670199B (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202510631395.3A Pending CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880085205.0A Active CN111670199B (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201
CN202510631395.3A Pending CN120860200A (zh) 2017-11-03 2018-11-02 用于治疗人癌瘤的单克隆抗体neo-201

Country Status (7)

Country Link
US (2) US11767367B2 (enExample)
EP (1) EP3735423A4 (enExample)
JP (3) JP7437307B2 (enExample)
CN (3) CN119587690A (enExample)
AU (2) AU2018360045B2 (enExample)
CA (1) CA3083467A1 (enExample)
WO (1) WO2019090134A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221544B2 (en) * 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN119053622A (zh) * 2022-04-12 2024-11-29 盛禾(中国)生物制药有限公司 一种抗ceacam5和ceacam6抗体及其应用
CN116699135B (zh) * 2022-04-29 2025-11-07 中国医学科学院肿瘤医院 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585476A4 (en) * 2010-06-22 2014-01-22 Neogenix Oncology Inc ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
EP3336104A1 (en) * 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
PL3160498T3 (pl) * 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
WO2018218230A1 (en) * 2017-05-26 2018-11-29 Etubics Corporation Combination immunotherapies comprising il-15 superagonists

Also Published As

Publication number Publication date
AU2025205420A1 (en) 2025-07-31
CN120860200A (zh) 2025-10-31
JP2024010054A (ja) 2024-01-23
JP7712338B2 (ja) 2025-07-23
US11767367B2 (en) 2023-09-26
JP2025148435A (ja) 2025-10-07
US20200362053A1 (en) 2020-11-19
EP3735423A1 (en) 2020-11-11
CN111670199A (zh) 2020-09-15
US20240101702A1 (en) 2024-03-28
JP7437307B2 (ja) 2024-02-22
WO2019090134A1 (en) 2019-05-09
CN111670199B (zh) 2025-06-17
JP2021502416A (ja) 2021-01-28
CA3083467A1 (en) 2019-05-09
AU2018360045A1 (en) 2020-05-21
EP3735423A4 (en) 2021-02-24
AU2018360045B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7712338B2 (ja) ヒトがんの治療のためのモノクローナル抗体ｎｅｏ－２０１
JP2019213530A (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
EP3261650A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
US20240400714A1 (en) Methods and compositions for targeting treg cells
KR20210007959A (ko) Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
Fantini et al. Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas
WO2020263796A1 (en) Anti-alpp car-t cell therapy
EP3293271A1 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
KR102693317B1 (ko) 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
CN108610422A (zh) 抑制pd-1/pd-l1信号通路的结合分子
WO2025077869A1 (en) Anti-ny-eso-1 antibodies and uses thereof
EP4352103A2 (en) Methods and compositions for treating hematological malignancies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination